Stockscreener 앱 받기
8.71
1.04%
0.09
시간 외 거래:
8.50
-0.21
-2.41%
전일 마감가:
$8.62
열려 있는:
$8.62
하루 거래량:
1.79M
Relative Volume:
0.73
시가총액:
$860.78M
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-18.53
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
-7.24%
1개월 성능:
-15.52%
6개월 성능:
-39.76%
1년 성능:
-42.70%
1일 변동 폭
$8.33
$8.78
1주일 범위
$8.3184
$9.46
52주 변동 폭
$8.3184
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.71 | 851.88M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
ARS Pharma (NASDAQ: SPRY) offers free virtual visit, $0 co-pay for neffy access - Stock Titan
105,000 Shares in ARS Pharmaceuticals, Inc. $SPRY Bought by Hussman Strategic Advisors Inc. - MarketBeat
Why ARS Pharmaceuticals Inc. stock could see breakout soonWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
How ARS Pharmaceuticals Inc. stock benefits from strong dollar2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
How ARS Pharmaceuticals Inc. stock trades during market volatilityTreasury Yields & Real-Time Volume Triggers - newser.com
Can ARS Pharmaceuticals Inc. hit a new high this monthJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com
Multi factor analysis applied to ARS Pharmaceuticals Inc.Weekly Profit Report & Daily Stock Momentum Reports - newser.com
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - The Manila Times
UPDATE -- ARS Pharma to Present Real-World Data on - GlobeNewswire
ARS Pharma (Nasdaq: SPRY) to present real-world neffy data: 1 late-breaking oral, 6 posters - Stock Titan
What drives ARS Pharmaceuticals Inc stock priceFlag and Pennant Patterns & Learn to Think Like a Long-Term Investor - earlytimes.in
Why ARS Pharmaceuticals Inc. stock could rally in 20252025 Geopolitical Influence & Consistent Profit Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
ARS Pharmaceuticals (NASDAQ: SPRY) to Host Q3 Results Webcast; Replay for 30 Days - Stock Titan
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results - Yahoo Finance
ARS Pharma Presents Late-Breaking Oral and Poster Sessions on Real-World Effectiveness of neffy® at ACAAI 2025 Annual Scientific Meeting - Quiver Quantitative
ARS Pharmaceuticals Inc. stock outlook for YEAR2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
ARS Pharma (Nasdaq: SPRY) shares 9 of 10 anaphylaxis cases treated with single-dose neffy - Stock Titan
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Weekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Investment Recap & Technical Pattern Based Signals - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this week2025 Investor Takeaways & Capital Efficiency Focused Strategies - newser.com
Reversal indicators forming on ARS Pharmaceuticals Inc. stockTrade Signal Summary & Expert Verified Stock Movement Alerts - newser.com
Applying chart zones and confluence areas to ARS Pharmaceuticals Inc.Weekly Gains Report & Weekly Market Pulse Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Market Sentiment Report & Short-Term High Return Strategies - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineDividend Hike & Daily Volume Surge Trade Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analystsTrade Volume Summary & Growth Focused Investment Plans - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.59 Amid Financial Struggles - Markets Mojo
Published on: 2025-11-02 04:08:25 - newser.com
How ARS Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Published on: 2025-11-01 01:27:58 - newser.com
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 52-Week LowWhat's Next? - MarketBeat
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsWeekly Stock Recap & Low Drawdown Investment Ideas - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.90 Amid Financial Struggles - Markets Mojo
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):